Trigeminal neuralgia
Conditions
Interventions
Coboteptin group:Snake venom neurotoxin treatment
Botulinum toxin group:Botulinum toxin treatment
Combination therapy group:Botulinum toxin treatment+Snake venom neurotoxin treatment
Sponsors
Second Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) meet the 2018 ICHD-3 diagnostic criteria for trigeminal neuralgia; 2) The pain site was the second and/or the third branch; 3) 75 years old>=age>=18 years old; 4) receiving no treatment or with poor response to current treatment; 5) signed informed consent.
Exclusion criteria
Exclusion criteria: 1) Hypersensitivity to botulinum toxin type A or cobra neurotoxin drugs; 2) combined neuromuscular diseases, such as myasthenia gravis, motor neuron disease; 3) complicated with severe liver and kidney dysfunction; 4) patients during pregnancy and lactation; 5) Medications that may damage the neuromuscular junction (e.g., aminoglycoside antibiotics, quinine) within one week prior to injection; 6) infection or fever at the injection site; 7) severe cognitive and psychiatric impairment; 8) glaucoma; 9) secondary trigeminal neuralgia, imaging examination showed space-occupying lesions; 10) Unwilling to cooperate to complete the relevant scales.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual analogue scale;Frequency of pain episodes;Onset of pain relief (> 50% decrease in VAS score from baseline); | — |
Secondary
| Measure | Time frame |
|---|---|
| response rate;Patient Global Impression of Changes;Hamilton Anxiety Scale;Hamilton Depression Scale;Pittsburgh Sleep Scale; | — |
Countries
China
Contacts
Public ContactWeifeng Luo
Second Affiliated Hospital of Soochow University
Outcome results
None listed